

therapy were given 4 months after the first course to treat the residual lacrimal gland tumour. After 12 months the lacrimal gland tumour was no longer visible on MRI (fig 1B) and the Schirmer test score was 7 mm. Vision was unchanged and the corneal slit-lamp appearance was normal. In addition to topical lubricants, the patient underwent temporary punctal occlusion with resorbable collagen plugs as therapy. No extraorbital manifestation of the MALT lymphoma occurred during the subsequent follow-up period.

Comment

Patients treated with radiation for orbital MALT lymphomas often suffer from eye-related side effects. In a recent paper, four of nine patients who received additional radiotherapy for orbital and/or conjunctival lymphoma suffered from dry eye, conjunctivitis and cataract. One of the patients eventually lost his sight due to radiation-induced retinopathy.¹ Particularly when lymphoma develops in the lacrimal gland, the therapeutic approach should aim to prevent further damage to the that gland.

Treatment with the anti-CD20 monoclonal antibody rituximab for ocular adnexal MALT lymphomas has been reported primarily in recurring conjunctival lymphomas.² Only a few studies also report on the treatment of lacrimal gland involvement.^{1,3,4} In a recent report, two patients with lacrimal gland lymphomas had a relapse after a median time of 5 months following primary rituximab therapy with one cycle of four weekly infusions.³ Rituximab therapy also had a beneficial effect on the salivary and lacrimal gland function in patients with primary Sjögren syndrome associated with MALT lymphoma of the parotid gland.⁵ Our patient presented with severe dry eye and a very low Schirmer test score. Notably, rituximab treatment led to significant relief of the patient's complaints and increased tear secretion. Rituximab may be considered as a first-line therapy for lacrimal MALT lymphoma when radiation therapy is expected to aggravate the dry eye symptoms or when a reduction in the tumour size is anticipated before radiation therapy. In our patient two courses of four weekly cycles of rituximab therapy led to a prolonged remission period.

Carsten Heinz

Department of Ophthalmology, St. Franziskus-Hospital Muenster, Muenster, Germany and Department of Ophthalmology, University of Duisburg-Essen, Duisburg, Germany

Hartmut Merz

Department of Pathology, University of Schleswig-Holstein, Luebeck, Germany

Matthias Nieschalk

Department of ENT, St. Franziskus-Hospital Muenster, Muenster, Germany

Heribert Mueller-Miny

Department of Radiology, St. Franziskus-Hospital Muenster, Muenster, Germany

Peter Koch

Department of Medicine Haematology/Oncology, University of Muenster, Muenster, Germany

Arnd Heiligenhaus

Department of Ophthalmology, St. Franziskus-Hospital Muenster, Muenster, Germany and Department of Ophthalmology, University of Duisburg-Essen, Duisburg, Germany

Correspondence to: Dr Carsten Heinz, Department of Ophthalmology, St. Franziskus-Hospital Muenster, Hohenzollernring 54, 48145 Muenster, Germany; carsten.heinz@uveitis-zentrum.de

Informed consent was obtained for publication of the person's details in this report.

doi: 10.1136/bjo.2007.115626

Accepted 30 January 2007

Competing interests: None.

References

- 1 **Charlotte F**, Doghmi K, Cassoux N, *et al*. Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. *Virchows Arch* 2006;**448**:506–16.
- 2 **Nuckel H**, Meller D, Steuhl KP, *et al*. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. *Eur J Haematol* 2004;**73**:258–62.
- 3 **Ferreri AJ**, Ponzoni M, Martinelli G, *et al*. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. *Haematologica* 2005;**90**:1578–9.
- 4 **Asproudis I**, Gorezis S, Charonis GC, *et al*. Mucosa-associated lymphoid tissue lymphoma of the lacrimal gland—a case report. *In Vivo* 2005;**19**:1105–9.
- 5 **Pijpe J**, van Imhoff GW, Vissink A, *et al*. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. *Ann Rheum Dis* 2005;**64**:958–60.

Efficacy of intravitreal triamcinolone for macular oedema due to CRVO after anti-androgen therapy for hirsutism in a young monocular female

After diabetic retinopathy, retinal venous occlusion (RVO) is the most common cause of retinopathy leading to severe visual loss in all age groups. Generally, RVO is associated with systemic diseases with significant morbidity and mortality. The risk of RVO is increased in patients older than 65 years of age with systemic hypertension, cardiovascular disease, diabetes and obesity.¹ Patients younger than 50 years of age may have other underlying conditions requiring appropriate investigation and treatment.^{2,3} We describe the development of central retinal venous occlusion (CRVO) and the efficacy of intravitreal triamcinolone acetonide injection (IVTA) for associated cystoid macular oedema (CME) in a young healthy woman after she was started on systemic multiple anti-androgen therapy for treatment of hirsutism.

Case report

A 24-year-old woman with a 4-month history of painless loss of vision and a diagnosis of CRVO in her left eye (OS) was referred for further evaluation and management. Her ocular history revealed squint surgery and amblyopia in her right eye (OD) since childhood. Since puberty she had had acne and hirsutism that were unsatisfactorily treated conservatively. Seven months earlier she had sought treatment for the hirsutism and was started on systemic multiple anti-androgen therapy that included Noractone (spironolactone) 25 mg three times daily, Androcur (cyproterone acetate) 25 mg twice daily and Diane-35 (cyproterone acetate 2 mg and ethinyl oestradiol 35 µg) once daily. These

medications were discontinued by a local ophthalmologist after the discovery of CRVO. The patient reported no other systemic disorder and family history was non-contributory. Her visual acuity (VA) was 20/300 in OD and 20/200 in OS with normal intraocular pressures. Slit-lamp examination was unremarkable with no evidence of rubiosis iridis in OS. Dilated fundus examination of OD was within normal limits; however, OS showed flame-shaped haemorrhages with tortuous dilated retinal veins (fig 1A). There was evidence of significant CME but no evidence of retinal neovascularisation on the disc or elsewhere. Intravenous fluorescein angiography of OS fundus showed delayed fillings and diffuse CME without any evidence of capillary non-perfusion or abnormal neovascularisation (fig 1B–D). Central macular thickness by optical coherence tomography was 736 µm (fig 1E). A diagnosis of non-ischaemic CRVO with extensive CME in OS was established. Her medical evaluation revealed normal blood pressure and physical examination. Mild microcytic hypochromic anaemia was noted in her laboratory work-up. Her erythrocyte sedimentation rate, protein electrophoresis, plasma viscosity, lipid profile, plasma homocysteine, sickling test, anti-phospholipid antibodies (cardiolipin antibodies IgG, IgM), plasma fibrinogen, lipoprotein A, abnormal factor V Leiden, factors VII, VIII, XII, anti-thrombin III, protein S, and protein C were normal. She had negative anti-nuclear antibody with non-reactive TPHA. Application of grid laser therapy to the macular area did not resolve her CME. However, a single injection of IVTA (4 mg/0.1 ml) resulted in a dramatic decrease in CME (fig 2A) and improvement of her VA to 20/50. The improvement in CME was verified by intravenous fluorescein angiography (IVFA; fig 2B,C) and optical coherence tomography (OCT; fig 2D), and was sustained over a 3-year follow-up period.

Discussion

Hirsutism (excessive hair growth), acne and seborrhea are distressing and common endocrine problems in women which may be difficult to manage conservatively. One cause of hirsutism is excessive androgen production by the ovaries. Anti-androgen regimes effective for hirsutism include spironolactone, cyproterone acetate and cyproterone acetate with ethinyl oestradiol (Diane-35).⁴ These medications suppress the release of gonadotrophin hormone, which reduces androgen production. Cyproterone used alone has a minor effect on blood clotting factors, however in combination with ethinyl oestradiol it enhances coagulation. Numerous reports have described vascular complications due to drugs after use of the oral contraceptive pill (OCP). Use of the OCP is known to be a risk factor for cardiovascular and cerebrovascular diseases and, as this report suggests, CRVO.⁵ Other serious ocular complications include branch RVO, artery occlusion and acute ischaemic optic neuropathy.^{5,6} Investigation in a 28-year-old CRVO patient treated with an anti-androgen drug revealed an abnormality of the haemostatic system; however, 1 month after the primary episode CRVO resolved and the fundus became normal without macular oedema.⁷ Our case suggests that anti-androgen therapy in young patients may result in CRVO. A single injection of IVTA (4 mg/0.1 ml) may be effective to resolve CRVO-associated CME and improve VA. To the best of our knowledge this is the first report




Figure 1 A baseline fundus photograph prior to treatment of OS (A) and intravenous fluorescein angiography of OS fundus, early phase (B), mid phase (C) and late phase (D); optical coherence tomography of macular area of OS (E).




Figure 2 Fundus photograph of the OS after a single intravitreal triamcinolone acetonide injection showing resolution of cystoid macular oedema (A), which was evident on intravenous fluorescein angiography (B, C) as well as on optical coherence tomography of the macular area (D).

of a case of CRVO due to multiple anti-androgen therapy in a young female with hirsutism. Patients should be informed of the potential side effects of such medications and warned that anti-androgen therapy may result in CRVO in addition to other possible thromboembolic disorders; the use of these drugs should be discouraged, especially in patients with monocular vision. These medications should be discontinued at the first sign of any visual disturbance and the patient should be carefully monitored for any signs of significant CME which can be treated with IVTA.

Hassan Al-Dhibi

Retina Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia

Imtiaz A Chaudhry

Oculoplastic and Orbit Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia

Annuod Al-Saati

Department of Ophthalmology, King Saud University, Riyadh, Saudi Arabia

Farrukh A Shamsi

Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia

Correspondence to: Dr Imtiaz A Chaudhry, Oculoplastic and Orbit Division, King Khaled Eye Specialist Hospital, PO Box 7191, Riyadh 11462, Saudi Arabia; orbitdr@hotmail.com

Informed consent was obtained for publication of the person's details in this report.

doi: 10.1136/bjo.2007.114843

Accepted 3 February 2007

Competing interests: None declared.

References

- 1 **The Eye Disease Case-Control Study Group.** Risk factors for central retinal vein occlusion. *Arch Ophthalmol* 1996;**114**:545–54.
- 2 **Dodson PM, Kritzinger EE.** Underlying medical conditions in young patients and ethnic differences in retinal vein occlusion. *Trans Ophthalmol Soc UK* 1985;**104**:114–19.

- 3 **Fong ACO, Shatz H.** Central retinal vein occlusion in young adults. *Surv Ophthalmol* 1993;**37**:393–417.
- 4 **Diane-35** [product monograph]. In: *Compendium of pharmaceuticals and specialties*. Ottawa: Canadian Pharmacists Association, 2002:493–5.
- 5 **Stowe GCIII, Zakov ZN, Albert DM.** Central retinal vascular occlusion associated with oral contraceptives. *Am J Ophthalmol* 1978;**86**:798–801.
- 6 **Glacet-Bernard A, Kuhn D, Soubrane G.** Ocular complications of hormonal treatments: oral contraception and menopausal hormonal replacement therapy. *Contracept Fertil Sex* 1999;**27**:285–90.
- 7 **Zaoui M, Cordebar B, Naoun-Hubert I, et al.** Central retinal vein occlusion in a patient treated with antiandrogenic drug. *J Fr Ophthalmol* 2000;**23**:42–4.

Fulminant orbital myiasis in the developed world

We present, to our knowledge, the first case of orbital myiasis documented in a patient treated with antiandrogenic drug. Ophthalmomyiasis is a rare infection

of Diptera fly larvae. The female flies have a particularly strong olfactory and visual attraction to blood, most commonly in ulcers from tumours, traumatic wounds or areas of compromised circulation.¹ Most cases of ophthalmomyiasis are limited to the larvae invading the superficial peri-ocular tissues or penetrating the palpebra, conjunctiva or sclera. However, the most severe form of the disease, orbital myiasis, is infestation and destruction of the entire orbital cavity. Fewer than 20 cases of orbital myiasis have been published worldwide, all of them in developing countries, and usually in association with basal cell carcinoma.^{2–5}

Case summary

A 65-year-old female with no past medical history initially presented to the emergency room (ER) for pain in the right eye (OD). Suspicion for orbital cellulitis was high given warmth, redness, oedema, decreased vision and restricted ocular motility OD. An orbital CT scan revealed soft tissue swelling in addition to bony erosions and a suspicious orbital mass. Biopsy of the mass showed squamous cell carcinoma without spread outside the orbit. The patient was offered exenteration at this time as a possible cure. However, she vehemently refused, so radiation therapy was undertaken and the mass was reduced 80% in size. Vision at this time was 20/40 OD.

The patient presented a second time 2 months later and vision was now 20/80 OD with an ulcerated mass just supero-temporal to




Figure 1 Axial computed tomography (CT) scans showing soft tissue swelling and bony erosions in the right eye (OD). In the left image it can be seen that the globe is deformed compared to the fellow eye. The radio dense linear opacity in the globe OD corresponds to intraocular infestation with maggots.